This report discusses the case of a patient with stage IV lung adenocarcinoma with an EGFR exon 19 mutation, detailing the course of the disease and the impact of various treatments, including the limited effectiveness of osimertinib on bone metastases [3]. This evidence concerns the gene EGFR and lung adenocarcinoma.